JP2016516061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516061A5 JP2016516061A5 JP2016503078A JP2016503078A JP2016516061A5 JP 2016516061 A5 JP2016516061 A5 JP 2016516061A5 JP 2016503078 A JP2016503078 A JP 2016503078A JP 2016503078 A JP2016503078 A JP 2016503078A JP 2016516061 A5 JP2016516061 A5 JP 2016516061A5
- Authority
- JP
- Japan
- Prior art keywords
- targeting agent
- antibody conjugate
- compound
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008685 targeting Effects 0.000 claims 67
- 239000003795 chemical substances by application Substances 0.000 claims 66
- 229940127121 immunoconjugate Drugs 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 37
- 235000001014 amino acid Nutrition 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 13
- -1 cRGD Chemical compound 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- SOAPXKSPJAZNGO-WDSKDSINSA-N (2s)-2-[[(1s)-1,3-dicarboxypropyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCC(O)=O SOAPXKSPJAZNGO-WDSKDSINSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 claims 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical group C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 108010073466 Bombesin Receptors Proteins 0.000 claims 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 1
- 108091005932 CCKBR Proteins 0.000 claims 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 claims 1
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 claims 1
- 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 claims 1
- 229940123687 Glycohydrolase inhibitor Drugs 0.000 claims 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 108010021290 LHRH Receptors Proteins 0.000 claims 1
- 102000008238 LHRH Receptors Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 102000003797 Neuropeptides Human genes 0.000 claims 1
- 108090000189 Neuropeptides Proteins 0.000 claims 1
- 102000017922 Neurotensin receptor Human genes 0.000 claims 1
- 108060003370 Neurotensin receptor Proteins 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 108010079943 Pentagastrin Proteins 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 108010043958 Peptoids Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 claims 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 claims 1
- 229940127174 UCHT1 Drugs 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- CFODQUSMSYDHBS-UHFFFAOYSA-N octreotate Chemical compound O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2[C]3C=CC=CC3=NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(O)=O)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 CFODQUSMSYDHBS-UHFFFAOYSA-N 0.000 claims 1
- 229960002700 octreotide Drugs 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 229960000444 pentagastrin Drugs 0.000 claims 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims 1
- 235000016491 selenocysteine Nutrition 0.000 claims 1
- 229940055619 selenocysteine Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims 1
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783426P | 2013-03-14 | 2013-03-14 | |
| US61/783,426 | 2013-03-14 | ||
| US201361839330P | 2013-06-25 | 2013-06-25 | |
| US61/839,330 | 2013-06-25 | ||
| PCT/US2014/029379 WO2014153164A1 (en) | 2013-03-14 | 2014-03-14 | Targeting agent antibody conjugates and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516061A JP2016516061A (ja) | 2016-06-02 |
| JP2016516061A5 true JP2016516061A5 (cg-RX-API-DMAC10.html) | 2017-04-27 |
| JP6501270B2 JP6501270B2 (ja) | 2019-04-17 |
Family
ID=51581385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503078A Active JP6501270B2 (ja) | 2013-03-14 | 2014-03-14 | 標的化剤抗体抱合体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20160017058A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP2970505A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6501270B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110420333A (cg-RX-API-DMAC10.html) |
| DK (1) | DK2968552T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2790420T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT2968552T (cg-RX-API-DMAC10.html) |
| WO (2) | WO2014153002A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN110437337B (zh) | 2013-02-26 | 2024-07-30 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| US20160017058A1 (en) | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| AU2014337385B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| AU2014337367B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| JP2017536341A (ja) * | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016065075A1 (en) | 2014-10-21 | 2016-04-28 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
| US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| MX386587B (es) | 2014-12-05 | 2025-03-19 | Genentech Inc | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. |
| CA3081058C (en) * | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| WO2016168766A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| US9988454B2 (en) * | 2015-05-20 | 2018-06-05 | Immunwork Inc. | Peptide core-based multi-arm linkers for treating central nervous system diseases |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| HK1253512A1 (zh) * | 2015-05-29 | 2019-06-21 | Amphivena Therapeutics, Inc. | 双特异性cd33和cd3结合蛋白质的使用方法 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| AU2016303485A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| WO2017055392A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
| JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子 |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| BR112018014585A2 (pt) | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
| ES2904593T3 (es) * | 2016-01-21 | 2022-04-05 | Pfizer | Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos |
| EP3851457A1 (en) * | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| US12252534B2 (en) | 2016-02-04 | 2025-03-18 | The Scripps Research Institute | Humanized anti-CD3 antibodies, conjugates and uses thereof |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| CN109152803B (zh) * | 2016-04-25 | 2022-09-23 | 普梭梅根公司 | 用于表征与皮肤相关的病症的方法和系统 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| HRP20251020T1 (hr) * | 2016-05-20 | 2025-10-24 | Harpoon Therapeutics, Inc. | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| WO2017218891A1 (en) * | 2016-06-17 | 2017-12-21 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
| CN109689692B (zh) | 2016-06-22 | 2021-11-12 | 本康生物制药（深圳）有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
| WO2018013481A1 (en) | 2016-07-11 | 2018-01-18 | Board Of Regents, The University Of Texas System | Recombinant polypeptides comprising selenocysteine and method for producing the same |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| JP7186400B2 (ja) | 2016-08-30 | 2022-12-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| CA3042683A1 (en) * | 2016-11-07 | 2018-05-11 | Coimmune, Inc. | Bispecific antibodies that modulate tlr-4 signaling and uses thereof |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| CN108203718A (zh) * | 2016-12-20 | 2018-06-26 | 上海生博生物医药科技有限公司 | 靶向EGFRvIII干扰PD-1降低肿瘤免疫逃逸的CAR-T载体及构建方法和应用 |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| CN110383071B (zh) * | 2017-01-31 | 2023-10-03 | 豪夫迈·罗氏有限公司 | 用于质谱的试剂 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| EP3595719A4 (en) * | 2017-03-16 | 2020-12-30 | Immunwork Inc. | LINKER UNITS AND MOLECULAR CONSTRUCTIONS WITH IT |
| US11124579B2 (en) | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| EP4759318A2 (en) | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| ES3068176T3 (en) * | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| EP3762027A4 (en) * | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| US20220002398A1 (en) * | 2018-06-07 | 2022-01-06 | Oncoone Research & Development Gmbh | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT |
| EP3844188A1 (en) | 2018-08-28 | 2021-07-07 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| JPWO2020071554A1 (ja) * | 2018-10-05 | 2021-09-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
| CN111744020B (zh) * | 2019-03-27 | 2024-07-05 | 中国科学院宁波材料技术与工程研究所 | 一种主动靶向响应型多肽药物、其制备方法和应用 |
| WO2020232303A1 (en) | 2019-05-14 | 2020-11-19 | Harpoon Therapeutics, Inc. | EpCAM BINDING PROTEINS AND METHODS OF USE |
| CN111995626B (zh) * | 2019-05-27 | 2023-06-27 | 首都医科大学 | 6-(乙酰-aa-巯基)嘌呤,其合成,活性和应用 |
| WO2020245076A1 (en) * | 2019-06-03 | 2020-12-10 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Eph2a aptamer and uses thereof |
| CN114222586A (zh) * | 2019-06-14 | 2022-03-22 | 斯克里普斯研究学院 | 免疫检查点阻断性双特异性分子 |
| CN112110923B (zh) * | 2019-06-21 | 2022-08-05 | 首都医科大学 | 6-S,9-N-(二乙酰-AA-OBzl-巯基)嘌呤,其合成,活性和应用 |
| CN112110924B (zh) * | 2019-06-21 | 2023-01-13 | 首都医科大学 | 6-S,9-N-(二乙酰-Lys-OBzl-巯基)嘌呤,其合成,活性和应用 |
| CN112110925B (zh) * | 2019-06-21 | 2023-06-27 | 首都医科大学 | 6-(乙酰-aa-巯基)嘌呤,其合成,与顺铂联用的活性和应用 |
| CN112125904B (zh) * | 2019-06-24 | 2022-09-02 | 首都医科大学 | 6-S,9-N-(二乙酰-AA-OBzl-巯基)嘌呤、其合成、活性和应用 |
| CN112125905B (zh) * | 2019-06-24 | 2023-04-07 | 首都医科大学 | 6-S,9-N-(二乙酰-Lys-OBzl-巯基)嘌呤、其合成、活性和应用 |
| CR20220330A (es) | 2019-12-13 | 2022-08-04 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso. |
| US20230056380A1 (en) * | 2020-01-31 | 2023-02-23 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| WO2021195513A1 (en) * | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
| BR112022019445A2 (pt) * | 2020-03-27 | 2022-12-13 | Ixaka France | Poli(beta-aminoésteres) direcionados |
| US12703750B2 (en) | 2020-04-11 | 2026-08-11 | Northwestern University | Humanized antibody targeting the tumor associated antigen IL13Ra2 |
| CN115003798B (zh) * | 2020-06-17 | 2025-08-01 | 兰迪·莱曼·阿伦 | 用于检测分析物的方法和试剂盒 |
| CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
| US20240043565A1 (en) * | 2020-10-15 | 2024-02-08 | Janux Therapeutics, Inc. | Antibodies targeting psma and cd3 and uses thereof |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP4240493A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN113018433B (zh) * | 2021-03-11 | 2023-01-17 | 湖南大学 | 一种免疫药物及其在肿瘤免疫治疗中的应用 |
| CN117396498A (zh) * | 2021-03-18 | 2024-01-12 | 威斯塔解剖学和生物学研究所 | 靶向IL13Rα2的DNA编码的双特异性抗体以及在癌症治疗中的使用方法 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| WO2023230582A1 (en) * | 2022-05-27 | 2023-11-30 | Enlaza Therapeutics, Inc. | Crosslinking multispecific antibodies |
| CN115368462B (zh) * | 2022-07-19 | 2026-01-02 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| BR0212897A (pt) * | 2001-09-21 | 2004-08-24 | Univ Tulane | Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| AU2004242845B2 (en) * | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US8574533B2 (en) | 2004-03-30 | 2013-11-05 | Kureha Corporation | Material for negative electrode of non-aqueous electrolyte secondary battery, process for producing the same, negative electrode and battery |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| EP1951890A4 (en) | 2005-11-16 | 2009-06-24 | Ambrx Inc | PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS |
| KR101423898B1 (ko) | 2005-12-14 | 2014-07-28 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도 |
| AU2006332809A1 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| AU2007215566A1 (en) | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
| CN101490087B (zh) * | 2006-05-30 | 2013-11-06 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| AU2007333737A1 (en) | 2006-12-18 | 2008-06-26 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US20100098630A1 (en) | 2006-12-28 | 2010-04-22 | Ambrx, Inc. | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides |
| DK2187965T3 (da) * | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| HRP20151367T1 (hr) | 2008-05-13 | 2016-01-29 | Yale University | Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka |
| PE20110480A1 (es) | 2008-09-26 | 2011-07-01 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales |
| US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| KR20200128601A (ko) | 2011-05-27 | 2020-11-13 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN104936985A (zh) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| US20160017058A1 (en) | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| WO2014185985A1 (en) | 2013-05-14 | 2014-11-20 | Ambrx, Inc. | Novel polypeptide small molecule conjugates and their uses |
| ES2648094T3 (es) | 2013-06-07 | 2017-12-28 | Rhizen Pharmaceuticals S.A. | Inhibidores de PI3 cinasa delta y gamma selectivos duales |
| AU2014337385B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| US12252534B2 (en) | 2016-02-04 | 2025-03-18 | The Scripps Research Institute | Humanized anti-CD3 antibodies, conjugates and uses thereof |
-
2014
- 2014-03-14 US US14/774,649 patent/US20160017058A1/en not_active Abandoned
- 2014-03-14 EP EP14771143.6A patent/EP2970505A4/en not_active Withdrawn
- 2014-03-14 JP JP2016503078A patent/JP6501270B2/ja active Active
- 2014-03-14 WO PCT/US2014/028612 patent/WO2014153002A1/en not_active Ceased
- 2014-03-14 US US14/774,647 patent/US10351626B2/en active Active
- 2014-03-14 DK DK14770731.9T patent/DK2968552T3/da active
- 2014-03-14 ES ES14770731T patent/ES2790420T3/es active Active
- 2014-03-14 PT PT147707319T patent/PT2968552T/pt unknown
- 2014-03-14 EP EP14770731.9A patent/EP2968552B1/en active Active
- 2014-03-14 WO PCT/US2014/029379 patent/WO2014153164A1/en not_active Ceased
- 2014-03-14 EP EP20162175.2A patent/EP3721902A1/en not_active Withdrawn
- 2014-03-14 CN CN201910610825.8A patent/CN110420333A/zh active Pending
- 2014-03-14 CN CN201480028567.8A patent/CN105283201B/zh active Active
-
2016
- 2016-09-16 US US15/268,389 patent/US20170002076A1/en not_active Abandoned
-
2019
- 2019-05-22 US US16/420,062 patent/US11377496B2/en active Active
-
2022
- 2022-06-22 US US17/847,054 patent/US20220396621A1/en not_active Abandoned